Company profile: Cutiss
1.1 - Company Overview
Company description
- Provider of regenerative medicine and skin tissue engineering solutions, including denovoSkin, a personalized bio-engineered skin graft for permanent treatment of skin defects and injuries; Viticell, a CE-marked cell therapy for vitiligo and dyspigmented burn scars; automated manufacturing of tissue therapies, clinical development programs, and named-patient basis treatment options.
Products and services
- DenovoSkin: A custom-engineered, personalized bio-engineered human skin graft comprising epidermal and dermal layers, delivering permanent treatment of skin defects and injuries with minimally scarring outcomes post-transplantation
- Clinical development program: A multi-phase series of Phase I–III trials architected to evaluate denovoSkin’s safety and efficacy in burns and reconstructive indications, generating rigorous clinical evidence
- Automated manufacturing process: An industrial-grade development process that automates tissue therapy production to decrease costs and time, enabling decentralization for broader access and streamlined scalability
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cutiss
Sofregen
HQ: United States
Website
- Description: Provider of silk-based medical implants and injectable biomaterials, including the Silk Voice Injectable Implant for vocal fold medialization and insufficiency, and injectable silk protein microparticle-based fillers for soft tissue augmentation and collagen production; previously offered the SERI Surgical Scaffold (discontinued as of Dec 31, 2021).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sofregen company profile →
Bonesupport
HQ: Sweden
Website
- Description: Provider of injectable osteoconductive biomaterials for treating fragility fractures from osteoporosis and bone voids or gaps caused by trauma, disease, or surgical procedures. Offers CERAMENT, a range of injectable osteoconductive and drug-eluting bioceramic products for bone voids and fractures that remodel to host bone within six to twelve months.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bonesupport company profile →
Regentys
HQ: United States
Website
- Description: Provider of early-stage regenerative medicine and innovative medical devices for gastrointestinal applications, including ECMH (Extracellular Matrix Hydrogel), a porcine-derived extracellular matrix hydrogel designed to create an environment favorable for new tissue growth to replace diseased or damaged tissue in the gastrointestinal tract.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regentys company profile →
BioD Logics
HQ: United States
Website
- Description: Provider of novel biologic products derived from placental tissues, engaged in the development and commercialization of biologics and focused on research into the regenerative potential of amnion and other placental tissues; a vertically integrated biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioD Logics company profile →
Meccellis Biotech
HQ: France
Website
- Description: Provider of biomaterials and tissue and cell engineering, creating biological implants in dialogue with surgeons. Products include CELLIS, a preservative-free dermal matrix for varied surgeries; CELLIS Breast, a porcine dermis matrix for breast reconstruction; and CELLIS Dental, a non-pyrogenic acellular membrane for dental soft tissue repair.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Meccellis Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cutiss
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cutiss
2.2 - Growth funds investing in similar companies to Cutiss
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cutiss
4.2 - Public trading comparable groups for Cutiss
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →